Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
A Japanese health ministry panel has endorsed a policy to accelerate the development, regulatory clearance, and stockpiling of medical countermeasures (MCMs) for priority infectious diseases — rare but potentially severe infections that spread sporadically into the country or emerge from…
To read the full story
Related Article
- Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Health Ministry Presents Proposal to Revise Priority Infectious Diseases
March 12, 2025
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- MHLW Council Endorses Early Approval Scheme for Medical Countermeasures
October 2, 2024
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
REGULATORY
- 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
March 13, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…